Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

Tambascia, Marcos Antônio; Geloneze, Bruno; Repetto, E.M.; Geloneze, Sylka Rodovalho; Picolo, Mayara Zaghi Dal; Magro, Daniéla Oliveira

doi:10.1046/j.1463-1326.2003.00285.x

Cited by 30 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Body weight and body fat distribution Mean age was 23.5 ± 1.1 (range [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] Figure 2), but this difference disappeared at the end of the run-in period (S, 87.6 ± 2.2 kg; D, 83.6 ± 3.8 kg; P ¼ 0.34). Percent change in body weight at the end of run-in period did not differ between groups (S, À5.3 ± 0.3%; D, À5.0 ± 0.4%).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

et al. 2007

View full text Add to dashboard Cite

Objective: To examine the effect of hypocaloric diet plus sibutramine on body composition, hormonal and metabolic parameters in overweight and obese patients with polycystic ovary syndrome (PCOS). Design: Open-label, randomized study at an outpatient clinic. Patients: A total of 59 overweight and obese (18-39 years old) women with PCOS. Measurements: All patients were placed in a hypocaloric diet plus sibutramine (10 mg per day) for the first month and then on a hypocaloric diet plus sibutramine (10 mg per day, group S) or hypocaloric diet only (group D) for the subsequent 6 months. Body composition, hormonal and metabolic features and insulin sensitivity (oral glucose tolerance test, OGTT) were evaluated at baseline and at 3 and 6 months of treatment. Results: Body weight reduced in both groups but the reduction was greater with sibutramine (À15.4±1.1 vs -11.1±1.9% in groups S and D, respectively, Po0.05). At 6 months, a greater percent of patients lost more than 10% of initial body weight in group S than D (81 vs 52.9%). In both groups, all women with abnormal OGTT at baseline presented normal glucose tolerance after 6 months. Free androgen index (FAI), glucose area under the curve and fasting triglyceride (TG) concentration were reduced after 6 months in group S only (Po0.05). No changes in cardiovascular risk factors, prolactin and hepatic enzymes levels were observed in both groups. Conclusion: A hypocaloric diet and a diet plus sibutramine both result in significant weight loss in overweight and obese women with PCOS. Patients who received sibutramine showed a greater weight loss and improvement in hyperandrogenemia and insulin sensitivity after 6 months of treatment. The amelioration of insulin resistance in this group could not be totally explained by weight loss. Total testosterone, FAI and TG levels reduction could be a possible mechanism. Finally, sibutramine increased compliance to diet and it was well tolerated from these patients.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The improvement in IR with sibutramine is in accordance with other studies. 24,33,34 It is difficult to speculate on the effect of sibutramine on IR. Central obesity and in particular the amount of visceral fat is associated with IR in obese patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Likewise, Hung et al (28) demonstrated that sibutramine treatment effectively reduced weight and enhanced insulin sensitivity without an alteration in serum adiponectin concentrations in obese type 2 diabetic patients. In other study, Tambascia et al (15) suggested that 6 months sibutramine treatment was effective in improving of HOMA-IR with no change in fibrinogen levels in the non-diabetic women. In the present study, mean levels of HOMA-IR in the obese did not change with 10 mg and 15 mg sibutramine treatment.…”

Section: Discussionmentioning

confidence: 92%

“…Elevated circulating levels of cytokines and inflammatory markers, such as interleukin-6 (IL-6), C-reactive protein (hsCRP) and tumor necrosis factor-alpha (TNF-α) have been implicated to play role in the obesity (16,19,21,22). Previous studies demonstrated that sustained weight loss was associated with reduction of cytokines (23,24) and improved insulin sensitivity (15,28). Marfella et al (25) suggested that mean levels of TNF-α and hsCRP were decreased in obese women that lost at least 10% of their original weight, after 1 year of a multidisciplinary program of weight reduction.…”

Section: Introductionmentioning

confidence: 99%

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

Sarac¹,

Saraç²

2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine ABS TRACTObjective: The aims of present study were 1) to evaluate cardiac valve characteristics, 2) to determine the plasma concentrations of fibrinogen, high sensitivity C-reactive protein (hsCRP), adiponectin, and tumor necrosis factor-α (TNF-α) in the obese women before and after 19 months sibutramine treatment in the obese women. Methods: Sixty obese women were enrolled in this prospective, randomized study. Thirty women received 10 mg once daily dose of sibutramine for 19 months. The rest of the obese women received 15 mg once daily dose of sibutramine for 19 months. All patients were evaluated with echocardiography. Plasma levels of adiponectin and TNF-α were measured by enzyme-linked immunosorbent assay (ELISA) and hsCRP by immunoturbimetric assay. Student paired and unpaired t tests were used to compare the 10 mg or 15 mg dose sibutramine effects either in groups or between the groups. Results: There were no signs of significant regurgitation or thickening of the mitral and aortic valves on echocardiographic evaluation performed after 19 months of treatment. Parameters of systolic function after 10 or 15 mg treatment were not different from pretreatment characteristics. Minimal tricuspid regurgitation was found in one (1/27) patient treated with 10 mg sibutramine after 19 months. Among obese patients treated with 15 mg sibutramine one patient (1/28) had minimal mitral valve regurgitation and 2 patients (2/28) had minimal aortic insufficiency. Stage II diastolic dysfunction in the 15 obese treated with 15 mg regressed to stage I diastolic dysfunction (50%). Stage II diastolic dysfunction in the 10 obese treated with 10 mg regressed to stage I diastolic dysfunction (33.3%). Mean levels of TNF-α(p=0.04), fibrinogen (p=0.03) and hsCRP (p=0.04)i decreased and adiponectin (p=0.03) levels increased in the obese treated with 10 mg sibutramine. Likewise, in the patients treated with 15 mg sibutramine, mean levels of TNF-α(p=0.01), fibrinogen (p= 0.02), and hsCRP (p= 0.04) decreased and adiponectin (p= 0.02) levels increased. Conclusion: Nineteen months of sibutramine treatment does not affect heart valve and systolic functions, however, diastolic dysfunction severity reduced with sibutramine treatment. Also In addition, mean levels of adiponectin, TNF-α, fibrinogen and hs-CRP change with 19 months sibutramine treatment. (Anadolu Kardiyol Derg 2010; 10: 226-32)

show abstract

“…Other studies, however, did not confirm this finding but demonstrated that the improvement in IR by the drug was dependent on weight reduction per se. 71,72 Until now, a direct action of sibutramine on IR is not proven.…”

Section: Sibutramine and Cardiometabolic Risk Factorsmentioning

confidence: 99%

The use of sibutramine in the management of obesity and related disorders: An update

Tzotzas¹,

Krassas²,

Τζιόμαλος³

et al. 2009

VHRM

View full text Add to dashboard Cite

Aims:To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results:The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on the lipid profile (mainly triglycerides and high density lipoprotein cholesterol), glycemic control and inflammatory markers in studies for up to one year. Preliminary studies showed that sibutramine may also improve other obesityassociated disorders such as polycystic ovary syndrome, left ventricular hypertrophy, binge eating disorder and adolescent obesity. The high discontinuation rates and some safety issues mainly due to the increase in blood pressure and pulse rate have to be considered. Additionally, it has not yet been established that treatment with sibutramine will reduce cardiovascular events and total mortality. Conclusions: Sibutramine, in conjunction with lifestyle measures, is a useful drug for reducing body weight and improving associated cardiometabolic risk factors and obesity-related disorders. Studies of longer duration are required to determine the precise indications of the drug, to evaluate safety issues and to assess its efficacy on cardiovascular mortality.

show abstract

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

Abstract: Sibutramine has demonstrated efficacy in reducing weight in non-diabetic women along with amelioration in insulin sensitivity and additional improvement in metabolic parameters.

Cited by 30 publications

References 32 publications

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

Cardiac valve evaluation and adipokine levels in obese women treated with sibutramine

The use of sibutramine in the management of obesity and related disorders: An update

Contact Info

Product

Resources

About